Opinion|Videos|July 3, 2024

Educating Patients on Complications Associated with CAR T-Cell Therapy

The panel provides clinical insights on talking with patients about complications associated with CAR T-cell therapy.

Episodes in this series

Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"

EP. 1 Identifying Potential Candidates for CAR T-Cell Therapy

Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"

EP. 2 Treating Patients Referred to Academic Centers for CAR T

Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"

EP. 3 CAR T-Cell Therapy: Leukapheresis Practices

Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"

EP. 4 Triaging and Prioritizing Patients with Multiple Myeloma

4 KOLs are featured in this program.

EP. 5 Transitioning Patients Back to Community Practices Following CAR T

4 KOLs are featured in this program.

EP. 6 Monitoring Adverse Events Following CAR T-Cell Therapy

4 KOLs are featured in this program.

EP. 7 Educating Patients on Complications Associated with CAR T-Cell Therapy

4 KOLs are featured in this program.

EP. 8 Improving Access for Patients Receiving CAR T-Cell Therapy

A panel of 4 experts on multiple myeloma

EP. 9 Collaborative Education for CAR T-Cell Therapy

EP. 10 Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings

EP. 10 Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings

Dr Park: What protocols and processes do you have in place at the community practice to continue monitoring and managing potential long-term complications or adverse events associated with CAR T-cell therapy?
1. How do you approach monitoring for and managing late-onset neurotoxicity or other long-term adverse effects that may occur after the patient transitions back to the community setting?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

September 27th, 2026

Applying the IMS/IMWG Definition of Cure in Community Myeloma Practice

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

September 26th, 2026

Managing Sustained MRD Negativity After Multiple Myeloma Therapy Ends

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

September 25th, 2026

Targeted Agents, Amyloidosis, and Defining a Cure in Plasma Cell Disorders

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

September 25th, 2026

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.

Rheumatoid arthritis RA in an autoimmune disease faultry activated b cells emitting antibodies which attack the joints causes inflammation front view 3d illustration. with copy space image | Image Credit © vxnaghiyev - stock.adobe.com

September 23rd, 2026

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

September 18th, 2026

NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

Trending on CancerNetwork

Acting on a HER2 Result and Navigating Access to Therapy

Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications

The Case for Frontline Zongertinib in HER2-Mutant NSCLC

Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC

Patient-Centered Treatment Transitions in HR+/HER2− mBC